Complications following permanent prostate brachytherapy

被引:130
作者
Stone, NN
Stock, RG
机构
[1] Mt Sinai Sch Med, Dept Urol, New York, NY 10028 USA
[2] Mt Sinai Sch Med, Dept Radiat Oncol, New York, NY 10028 USA
关键词
prostate brachytherapy; prostate cancer morbidity; prostate interstitial therapy;
D O I
10.1016/S0302-2838(02)00019-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The acute and chronic complications of permanent prostate brachytherapy are discussed. Materials and Methods: Review of literature for the complications associated with iodine-125 (I-125) and palladium-103 (Pd-103) prostate brachytherapy. Acute complications included urinary retention, changes in the International Prostate Symptom Score (IPSS) and need for TURP. Chronic morbidity included permanent urinary symptoms, incontinence, radiation proctitis and erectile dysfunction. Results: Urinary retention occurred in 1.5-22% of the patients postimplant. Acute urinary symptoms increased by over 100% 1 month after the procedure. By 12 months, the symptoms were either back to baseline or slightly elevated in over 90% of the patients. Significant obstructive symptoms or persistent urinary retention necessitating TURP-occurred in 0-8.7%. Urinary incontinence was found in 0-19% treated by implant without associated TURP, in 0-85% for those who had a TURP prior to the implant and in 0-17% for those who had the TURP subsequent to the implant. Potency rates ranged from 34% to 86% 1-6 years postimplant. Radiation proctitis was found in 0.5-21.4%, with significant injury (fistula) occurring in 1-2.4%. Conclusions: The data from this report suggests that permanent prostate brachytherapy can be accomplished with minimal short- and long-term morbidity. Attention to detail as well as an appreciation to the causative factors for the morbidity will help reduce treatment-related side effects. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 54 条
  • [1] [Anonymous], J UROL MED CHIR
  • [2] SHORT-TERM MORBIDITY FROM CT-PLANNED TRANSPERINEAL I-125 PROSTATE IMPLANTS
    ARTERBERY, VE
    WALLNER, K
    ROY, J
    FUKS, Z
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (04): : 661 - 667
  • [3] Complications after prostate brachytherapy in the medicare population
    Benoit, RM
    Naslund, MJ
    Cohen, JK
    [J]. UROLOGY, 2000, 55 (01) : 91 - 96
  • [4] Biochemical disease-free survival following I-125 prostate implantation
    Beyer, DC
    Priestley, JB
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03): : 559 - 563
  • [5] PROSTATE-SPECIFIC ANTIGEN BASED DISEASE-CONTROL FOLLOWING ULTRASOUND-GUIDED (125)IODINE IMPLANTATION FOR STAGE T1/T2 PROSTATIC-CARCINOMA
    BLASKO, JC
    WALLNER, K
    GRIMM, PD
    RAGDE, H
    [J]. JOURNAL OF UROLOGY, 1995, 154 (03) : 1096 - 1099
  • [6] BLASKO JC, 1991, SCAND J UROL NEPHROL, P113
  • [7] Urinary morbidity with a modified peripheral loading technique of transperineal 125I prostate implantation
    Brown, D
    Colonias, A
    Miller, R
    Benoit, R
    Cohen, J
    Arshoun, Y
    Galloway, M
    Karlovits, S
    Wu, A
    Johnson, M
    Quinn, A
    Kalnicki, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (02): : 353 - 360
  • [8] CRITZ FA, 1995, CANCER-AM CANCER SOC, V75, P2383, DOI 10.1002/1097-0142(19950501)75:9<2383::AID-CNCR2820750931>3.0.CO
  • [9] 2-Z
  • [10] DATTOLI M, 1996, INT J RADIAT ONCOL, V35, P1